Advertisement

A Controlled Study of Intra-Articular Hyalgan® in the Treatment of Osteoarthritis of the Knee

  • Roberto Fiorentini
  • Frank C. Dorsey
  • Sharon A. Segal
  • Roland Moskowitz

Abstract

A US multicenter clinical trial was undertaken to evaluate the safety and effectiveness of Hyalgan®, a defined molecular weight fraction of highly purified hyaluronic acid (500–730 kDa), prepared as a buffered solution in physiologic saline. Hyalgan is injected intra-articularly for the sustained relief of pain and joint dysfunction in osteoarthritis of the knee. This product is classified as a device according to the current ruling of the US Food and Drug Administration (FDA). However, this categorization may be questionable. Other regulatory authorities consider hyaluronic acid products as drugs because the mechanism of action appears to go beyond the mere physical function of replacing abnormal synovial fluid (“viscosupplementation”).

Keywords

Hyaluronic Acid Synovial Fluid Test Group Test Product Success Criterion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ohnhaus, E. E. and Adler, R. 1975. Methodological problems in the measurement of pain: a comparison between verbal rating scale and the visual analogue scale. Pain 1:379–384.CrossRefGoogle Scholar
  2. 2.
    Sriwatanakul, K., Kelvie, W., Lasagna, L., Calimlim, J. F., Weis, O. F., and Mehta, G. 1983. Studies with different types of visual analog scales for measurement of pain. Clin. Pharmacol. Ther. 34:234–239.CrossRefGoogle Scholar
  3. 3.
    Dougados, M., Nguyen, M., Listrat, V., and Amor, B. 1993. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cart. 1:92–103.CrossRefGoogle Scholar
  4. 4.
    Bellamy, N. and Buchanan, W. W. 1993. Clinical evaluation in rheumatic diseases. In Arthritis and Allied Conditions: A Textbook of Rheumatology (McCarty D.J. and Koopman W.J. eds.). Lea & Febiger, Philadelphia, pp. 157–172.Google Scholar
  5. 5.
    Williams, H. J., Ward, J. R., Egger, M. J., Neuner, R., Brooks, R. H., Clegg, D. O., Field, E. H., Skosey, J. L., Alarcón, G. S., Willkens, R. F., Paulus, H. E., Russell, I. J., and Sharp, J. T. 1993. Comparison of naproxen and acetaminophen—a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 36:1196–1206.CrossRefGoogle Scholar
  6. 6.
    Bradley, J. D., Brandt, K. D., Katz, B. P., Kalasinski, L. A., and Ryan, S. I. 1991. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N. Engl. J. Med. 325: 87–91.CrossRefGoogle Scholar
  7. 7.
    Formiguera Sala, S. and Esteve de Miguel, R. 1995. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a short term study. Eur. J. Rheumatol. Inflamm. 15:33–38.Google Scholar
  8. 8.
    Huskisson, E. C. 1995. Randomized, placebo-controlled study to compare the effectiveness of, and the patient satisfaction with intra-articular HYALGAN® in the treatment of osteoarthritis of the knee. Final report dated 12 June.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Roberto Fiorentini
  • Frank C. Dorsey
  • Sharon A. Segal
  • Roland Moskowitz

There are no affiliations available

Personalised recommendations